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In this issue of the Revista Brasileira de Hematologia e Hemoterapia, Cancela et al.(1) 
analyzed the incidence and the risk factors for central nervous system (CNS) relapse in children 
and adolescents with acute lymphoblastic leukemia (ALL) treated using the GBTLI-ALL 99 
protocol and found that a leukocyte count > 50 x 109/L at diagnosis was the only significant 
factor associated with a high incidence of CNS relapse.
Leukemic infiltration of the CNS is defined as five or more leukocytes/mm3 and blast 
cells in cerebrospinal fluid (CSF) or cranial nerve palsy(2). It is a well-established prognostic 
factor in children with ALL(2-6). The cumulative incidence of CNS relapse (combined or 
isolated) presently varies from 2.6 to 9.5%(7). No clinical or morphological CNS involvement 
is evident at diagnosis in about 60% of patients who eventually develop CNS relapse(3-6,8-10).
Similar to systemic chemotherapy in the treatment of systemic ALL, there is a growing 
concern to identify factors associated with increased risk of leukemia infiltration of the CNS 
and to consequently adapt the protocol aimed at the treatment and prophylaxis of neurological 
involvement(11). Several risk factors have been associated with a higher incidence of initial 
involvement or relapse in CNS, such as high risk genetic abnormalities [t(9;22) and mixed lineage 
leukemia (MLL) rearrangements], T-lineage ALL and high peripheral leukemic-cell burden(7,12).
Some studies have also demonstrated that patients with any identifiable blast cells in CSF, 
or CSF contamination by blastic cells during traumatic lumbar puncture, present an increased 
risk of CNS relapse(13-15). Others however have not found this association(16-18). Conventional 
cytological analysis has proved useful, but the analysis of cells in CSF, especially with 
low cell counts, is more difficult than is widely admitted and it is not always conclusive(19). 
Molecular involvement detected by more sensitive and specific techniques such as PCR and 
direct sequencing has been shown in around 45% of pediatric patients; the prognostic impact 
of this molecular involvement seems to be dependent of the intensity of treatment(20,21). It is 
possible that morphological involvement of the CNS would represent one of the extremes of a 
clinical spectrum ranging from gross to minimal residual disease involvement of the CNS and 
that molecular involvement could reflect biologically more aggressive disease.
The explanation for these discrepancies is probably related to the efficacy of systemic 
and CNS-directed therapy in different treatment regimens, suggesting that the poor prognosis 
associated with these variables can be overcome by more effective therapy(21).
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